BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) ...

The King of Prussia company's CEO said the layoffs are necessary in an industry being reshaped by new technologies, ...

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

Vertex Pharmaceuticals VRTX is scheduled to report its first-quarter 2026 results on May 4, after market close. The Zacks ...

Importantly, it could work for all CF patients, whereas Vertex Pharmaceuticals' medicines target only those with certain ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

As growth in Vertex's cystic fibrosis portfolio buoys the company amid the launch of gene therapy Casgevy, the company is feeling confident enough to boost its revenue outlook for the year. After ...

The market expects Vertex Pharmaceuticals (VRTX) to deliver a year-over-year increase in earnings on higher revenues when it ...

In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for ...

"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions ...

View Vertex, Inc. Class A VERX stock quote prices, financial information, real-time forecasts, and company news from CNN.